Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BrainAurora Medical Technology Limited ( (HK:6681) ) just unveiled an update.
BrainAurora Medical Technology Limited has scheduled a board meeting for March 31, 2026 to review and approve the group’s audited annual results for the financial year ended December 31, 2025. The meeting will also authorize publication of the full-year figures, a key step for investor disclosure and regulatory compliance on the Hong Kong Stock Exchange.
The announcement signals that BrainAurora is moving into the final phase of its annual reporting cycle, with forthcoming results likely to inform market views on its operational performance and strategic progress in the medical technology sector. The confirmed board composition, spanning executive, non-executive and independent non-executive directors, underlines established corporate governance arrangements as the company prepares to update stakeholders on its 2025 performance.
The most recent analyst rating on (HK:6681) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.
More about BrainAurora Medical Technology Limited
BrainAurora Medical Technology Limited is a Hong Kong–listed medical technology company incorporated in the Cayman Islands. The group operates in the healthcare sector, focusing on medical technology solutions and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a conventional Hong Kong corporate governance structure for listed medtech firms.
Average Trading Volume: 27,963,423
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.89B
For a thorough assessment of 6681 stock, go to TipRanks’ Stock Analysis page.